Results 31 to 40 of about 4,214,171 (152)

Additional file 3 of Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)

, 2022
Additional file 3. Supplementary Methods.
Grzmil, Michal, Boersema, Paul, Sharma, Ashish, Blanc, Alain, Imobersteg, Stefan, Pruschy, Martin, Picotti, Paola, Schibli, Roger, Behe, Martin   +8 more
openaire   +1 more source

Targeted Radiotherapeutics from 'Bench-to-Bedside'

CHIMIA, 2020
he concept of targeted radionuclide therapy (TRT) is the accurate and efficient delivery of radiation to disseminated cancer lesions while minimizing damage to healthy tissue and organs.
Cristina Müller, Martin Béhé, Susanne Geistlich, Nicholas P. van der Meulen, Roger Schibli   +4 more
doaj   +1 more source

Additional file 2 of Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)

, 2022
Additional file 2. Supplementary Table S1–S7.
Grzmil, Michal, Boersema, Paul, Sharma, Ashish, Blanc, Alain, Imobersteg, Stefan, Pruschy, Martin, Picotti, Paola, Schibli, Roger, Behe, Martin   +8 more
openaire   +1 more source

Subcellular Targeting of Theranostic Radionuclides

Frontiers in Pharmacology, 2018
The last decade has seen rapid growth in the use of theranostic radionuclides for the treatment and imaging of a wide range of cancers. Radionuclide therapy and imaging rely on a radiolabeled vector to specifically target cancer cells. Radionuclides that
Bas M. Bavelaar, Boon Q. Lee, Martin R. Gill, Nadia Falzone, Katherine A. Vallis   +4 more
doaj   +1 more source

Additional file 1 of Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)

, 2022
Additional file 1. Supplementary Figure S1–S5.
Grzmil, Michal, Boersema, Paul, Sharma, Ashish, Blanc, Alain, Imobersteg, Stefan, Pruschy, Martin, Picotti, Paola, Schibli, Roger, Behe, Martin   +8 more
openaire   +1 more source

Preclinical Evaluation of a ⁶⁴Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma

Pharmaceutics, 2023
Although the concept of theranostics is neither new nor exclusive to nuclear medicine, it is a particularly promising approach for the future of nuclear oncology.
Cassandra Métivier, Patricia Le Saëc, Joëlle Gaschet, Catherine Chauvet, Séverine Marionneau-Lambot, Peter O. Hofgaard, Bjarne Bogen, Julie Pineau, Nathalie Le Bris, Raphaël Tripier, Cyrille Alliot, Férid Haddad, Michel Chérel, Nicolas Chouin, Alain Faivre-Chauvet, Latifa Rbah-Vidal   +15 more
doaj   +1 more source

Targeted Radionuclide Therapy of Cancer and Infections

, 2023
Targeted radionuclide therapy (TRT) has been burgeoning worldwide, with several radiopharmaceuticals for the treatment of metastatic cancers being approved for clinical use [...
Ekaterina Dadachova, Bart C. H. van der Wal   +1 more
core   +1 more source

Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases

EJNMMI Physics, 2020
Background Targeted radionuclide therapy (TRT) is gaining importance. For TRT to be also used as adjuvant therapy or for treating minimal residual disease, there is a need to increase the radiation dose to small tumours.
Mario E. Alcocer-Ávila, Aymeric Ferreira, Michele A. Quinto, Clément Morgat, Elif Hindié, Christophe Champion   +5 more
doaj   +1 more source

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

Toward Personalized Theranostics: A Modular PET Platform for Antibody‐Based Imaging and Therapy

Advanced Science, Volume 13, Issue 62, 9 November 2026.
This modular, site‐specific antibody platform enables customizable conjugates for PET imaging and therapy. Interchangeable payloads – including radiometals, cytotoxics, and fluorophores – support adaptable, multimodal applications with limited off‐target effects. In vivo, the DFO/DOTAGA bischelate immunoconjugate provided clear tumor delineation in PET/
Delphine Vivier, Megane Grah Kple, Julen Ariztia, Marion Leroux, Mathieu Moreau, Michael Claron, Maxime Cheveau, Adam Laouafa, Agnieszka Kownacka, Camille Petitot, John Simonet, Alexandre M. M. Dias, Sophie Poty, Charles Truillet, Bertrand Collin, Alexandra Oudot, Franck Denat   +16 more
wiley   +1 more source